



Sheet 1 of 3

SUBSTITUTE FORM 1043 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	08582/014002
		Serial No.	10/505,375
		Applicant	Fong et al.
		Filing Date	May 10, 2005
		Group	1632
		IDS Filed	October 31, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
gH	US 5,328,688	Jul. 12, 1994	Roizman
	US 5,585,096	Dec. 17, 1996	Martuza et al.
	US 6,139,834	Oct. 31, 2000	Martuza et al.
	US 6,172,047	Jan. 9, 2001	Roizman
	US 6,770,274	Aug. 3, 2004	Martuza et al.
	US 7,064,111	Jun. 20, 2006	Todo et al.
	US 20020019362	Feb. 14, 2002	Weichselbaum et al.
	US 20020071832	June 13, 2002	Fong et al.
	US 20020187163	Dec. 12, 2002	Johnson et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
gH	WO 9712623	Apr. 10, 1997	WIPO	
	WO 0040734	Jul. 13, 2000	WIPO	
	WO 00/76553	Dec. 21, 2000	WIPO	
	WO 0191789	Dec. 6, 2001	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
gH	Azuma et al., Stimulation of host-defense mechanism with synthetic adjuvants and recombinant cytokines against viral infection in mice. Adv Exp Med Biol, 1992. 319: p. 253-63.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	08582/014002
		Serial No.	10/505,375
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Fong et al.
		Filing Date	May 10, 2005
		Group	1632
(37 C.F.R. § 1.98(b))		IDS Filed	October 31, 2007

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
97	Carroll et al., Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. <i>Annals of Surgery</i> , 1996. 224(3): p. 323-329.
	Chen et al., Combination gene therapy for liver metastasis of colon carcinoma in vivo. <i>Proc Natl Acad Sci U S A</i> , 1995. 92(7): p. 2577-81.
	Delman et al., Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. <i>Hum Gene Ther</i> , 2000. 11(18): p. 2465-72.
	Ebright et al., Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. <i>J Thorac Cardiovasc Surg</i> , 2002. 124(1): p. 123-9.
	Eck et al., Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. <i>Hum Gene Ther</i> , 1996. 7(12): p. 1465-82.
	Fong et al. Phase I study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. in ASCO. 2002.
	Fu and Zhang, Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. <i>Cancer Res</i> , 2002. 62(8): p. 2306-12.
	Harrington et al., Gene therapy for prostate cancer: current status and future prospects. <i>J Urol</i> , 2001. 166(4): p. 1220-33.
	Jarnagin et al., Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. <i>Ann Surg</i> , 2000. 231(5): p. 762-71.
	Karpoff et al., Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon. <i>J Clin Invest</i> , 1997. 99(4): p. 799-804.
	MacKie et al., Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. <i>Lancet</i> , 2001. 357(9255): p. 525-6.
	Nakamura et al., Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. <i>Cancer Res</i> , 2001. 61(14): p. 5447-52.
	Nakamura et al., Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. <i>J Clin Invest</i> , 2002. 109(7): p. 871-82.
↓	Nakano et al., Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. <i>Mol Ther</i> , 2001. 3(4): p. 431-7.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No. 08582/014002 Serial No. 10/505,375 Applicant Fong et al. Filing Date May 10, 2005 Group 1632 IDS Filed October 31, 2007
--	--

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
9H	Oldfield et al., Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther, 1993. 4(1): p. 39-69.
	Oyama et al., Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther, 2000. 11(12): p. 1683-93.
	Pawlik et al., Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer, 2002. 95(5): p. 1171-81.
	Toda et al., Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther, 2002. 9(4): p. 356-64.
	Toda et al., In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol, 1998. 160(9): p. 4457-64.
	Toda et al., Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther, 2001. 8(4): p. 332-9.
	Toda et al., Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther, 1998. 9(15): p. 2177-85.
	Todo et al., Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther, 1999. 10(17): p. 2741-55.
	Walker et al., Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther, 1999. 10(13): p. 2237-43.
	Yoon et al., An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. Faseb J, 2000. 14(2): p. 301-11.
↓	Yoon et al., Influence of p53 on herpes simplex virus type 1 vectors for cancer gene therapy. J Gastrointest Surg, 1999. 3(1): p. 34-48.

EXAMINER <i>Don He</i>	DATE CONSIDERED 1/4/08
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	